The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global digital diabetes management market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 21% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
Digital diabetes management refers to electronic medical solutions used for remote monitoring, analysis and management of patients with diabetes. Diabetes is a metabolic disorder that leads to elevated blood sugar levels in the body. Digital diabetes management involves the use of software-based applications, platforms and devices, such as smart glucose meters, insulin pens, sensors, closed-loop systems and insulin patches. These systems are used to manage blood glucose, pressure and cholesterol levels and effectively track and maintain the record of the patients. They also aid in improving healthcare processes, delay or prevent diabetes complications and minimize medical costs for the patients. As a result, they are widely used across at-home and self-care facilities, hospitals, clinics and research institutes.
The increasing prevalence of diabetes and obesity across the globe is one of the key factors driving the growth of the market. Moreover, rising health consciousness among the masses is providing a thrust to the market growth. Patients suffering from diabetes related disorders and are widely adopting digital diabetes management solutions and advanced devices, such as smart insulin pens, that can record the amount of each dosage and transmit the related data. Additionally, various technological advancements, such as the integration of connected devices with the Internet of Things (IoT), artificial intelligence (AI) and big data solutions, are acting as other growth-inducing factors. These innovative systems are used by both patients and healthcare providers to receive customized and real-time updates regarding the hypoglycemic index of the patient. Solution providers are also designing user-friendly systems and wearable devices to facilitate self-monitoring of blood glucose levels. Other factors, including rising healthcare expenditures of the masses, along with rapid digitization of the medical industry, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global digital diabetes management market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product type and device type.
Breakup by Product Type:
Breakup by Device Type:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, ACON Laboratories Inc, Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation), Becton, Dickinson and Company, Dexcom Inc., F. Hoffmann-La Roche AG, Medtronic plc, Novo Nordisk A/S, Tandem Diabetes Care Inc. and Terumo Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Device Type, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, ACON Laboratories Inc, Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation), Becton, Dickinson and Company, Dexcom Inc., F. Hoffmann-La Roche AG, Medtronic plc, Novo Nordisk A/S, Tandem Diabetes Care Inc. and Terumo Corporation.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at